Effects of Fampridine in People with Multiple Sclerosis: A Systematic Review and Meta-analysis

@article{Valet2019EffectsOF,
  title={Effects of Fampridine in People with Multiple Sclerosis: A Systematic Review and Meta-analysis},
  author={Maxime Valet and M{\'e}lanie Quoilin and Thierry Lejeune and G. Stoquart and Vincent van Pesch and Souraya El Sankari and Christine Detrembleur and Thibault Warlop},
  journal={CNS Drugs},
  year={2019},
  volume={33},
  pages={1087 - 1099}
}
Prolonged-release (PR) fampridine is a potassium channel blocker used as a symptomatic treatment for walking disability in patients with multiple sclerosis (MS). Its clinical effects in such patients have not been systematically reviewed, and may be more wide-ranging than expected. To summarize the evidence on the effects of PR fampridine in patients with MS. A systematic search of Pubmed, Scopus (including EMBASE), and PsycINFO (completed in 01/2019) was carried out to identify randomized… 
Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials
TLDR
Dalfampridine exerts positive effects on walking ability, finger dexterity, and cognitive function in MS, and should be administered under the guidance of a physician or pharmacist given the higher incidence of adverse events.
Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years
TLDR
The data demonstrate significant positive effects of treatment with PR-fampridine over 2 years on different cognitive domains as well as fatigue and depression in a cohort of PwMS and imply that PR- fampridines should be considered as symptomatic treatment improving aspects of cognition, fatigue and Depression in Pw MS.
A Prospective, Observational, Cohort Study to Assess the Efficacy and Safety of Prolonged-Release Fampridine in Cognition, Fatigue, Depression, and Quality of Life in Multiple Sclerosis Patients: The FAMILY Study
TLDR
New data is provided in support of PR-FAM’s positive effects in cognition, fatigue, depression, and QoL in a large, heterogeneous group of Greek MS patients in the real-world setting.
Efficacy and safety of fampridine for walking disability in multiple sclerosis.
TLDR
The tolerance is good, with mild to moderate, and transient adverse events, the most commonly reported are insomnia, headache, fatigue, back pain, dizziness, nausea and balance disorders.
Effects of prolonged-release fampridine on multiple sclerosis-related gait impairments. A crossover, double-blinded, placebo-controlled study.
TLDR
Prolonged release-fampridine increases knee flexion during swing phase and lowers mechanical external work and whether these changes are related to clinically meaningful improvements in walking capacity and other functional variables should be further investigated.
Treating MS After 50: the Role of Age in Therapeutic Decision-Making
  • L. Hua
  • Current Treatment Options in Neurology
  • 2021
Purpose of Review This review presents the latest evidence available regarding treating patients with MS over age 50. This includes what is known about disease-modifying therapies, symptomatic
Nabiximols plus robotic assisted gait training in improving motor performances in people with Multiple Sclerosis.
TLDR
The results suggest that the combined THC:CBD-RAGT approach could be useful in improving gait performance in patients with MS.
Clinical assessment, management and rehabilitation of walking impairment in MS: An Expert Review.
TLDR
This review further highlights strategies that may restore walking function including pharmacological symptomatic treatment and non-pharmacological rehabilitation approaches such as exercise and task specific training providing an appraisal of mobility targeted therapies to be considered when planning multidisciplinary comprehensive-care of pwMS.
Employ FTIR spectroscopic method for determination of certain multiple sclerosis medications in plasma and pharmaceutical formulations
Abstract A selective, simple, rapid, green, cost-effective, and non-destructive assay was proposed for the simultaneous quantitation of Fampridine (FPN), Dexamethasone (DMS), and Fluoxetine (FLX) in
The role of voltage-gated ion channels in visual function and disease in mammalian photoreceptors.
TLDR
This review will discuss two types of voltage-gated ion channels present in photoreceptors, focussing on their structure and physiology, and their role in visual processing.
...
1
2
...

References

SHOWING 1-10 OF 52 REFERENCES
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial
TLDR
Fampridine improved walking ability in some people with multiple sclerosis, and was associated with a reduction of patients' reported ambulatory disability, and is a clinically meaningful therapeutic benefit.
Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29
TLDR
This analysis evaluated the physical and psychological health outcomes of subjects with progressing or relapsing MS from individual items of the Multiple Sclerosis Impact Scale (MSIS-29) and found that PR-fampridine resulted inPhysical and psychological benefits versus placebo, sustained over 24weeks.
4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review
This systematic review summarizes the existing evidence on the effect of 4-aminopyridine (4-AP) as a symptomatic treatment of decreased walking capacity in patients with multiple sclerosis (MS) when
The effect of Fampridine-SR on cognitive fatigue in a randomized double-blind crossover trial in patients with MS.
TLDR
Although this small pilot study does not suggest that Fampridine-SR results in a statistically significant improvement of CF in MS patients, as compared to placebo, individuals demonstrated an improvement in both information processing speed and CF, suggesting further studies are warranted.
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
TLDR
An evidence-based clinical practice guideline for the pharmacological treatment of people with MS, which takes into account all disease-modifying drugs approved by the European Medicine Agency at the time of publication.
Dose comparison trial of sustained-release fampridine in multiple sclerosis
TLDR
This phase 2 study suggests that a subgroup of patients, when treated with fampridine, experiences a clinically relevant improvement in walking ability, which is sustained for at least 14 weeks.
Fampridine treatment and walking distance in multiple sclerosis: A randomised controlled trial
TLDR
The study provides evidence that fampridine may improve walking distance in MS and indicates that nerve excitability assessment may assist in identifying those patients most likely to respond to fampsridine.
Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis
TLDR
Efficacy and tolerability data confirmed PR fampridine as a valuable long-term treatment for improving ambulatory function in gait-impaired PwMS and emphasizes the importance of regular reassessment of drug efficacy in clinical practice to optimize treatment.
Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study
TLDR
Improvements were seen in lower extremity muscle strength and walking speed in the Fampridine-SR group compared to placebo and there were no significant differences in other MSFC measure or fatigue scores.
Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years
TLDR
The data demonstrate significant positive effects of treatment with PR-fampridine over 2 years on different cognitive domains as well as fatigue and depression in a cohort of PwMS and imply that PR- fampridines should be considered as symptomatic treatment improving aspects of cognition, fatigue and Depression in Pw MS.
...
1
2
3
4
5
...